Daiichi Sankyo and Merck team up on $22 billion collaboration for Sankyo’s antibody drug conjugates

(Reuters) – Daiichi Sankyo and Merck have entered into an agreement worth up to $22 billion for three of Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candidates, the companies said on Thursday.

(Reporting by Kanjyik Ghosh in Bengaluru; Editing by Subhranshu Sahu)